BRCA1 and breast cancer: These 14 samples included one BRCA1-defective sample (sc5rJUQ033), which we assumed to be HRD, and one Stage II Luminal A sample (sc5rJUQ064) which we assumed to be HR-proficient, given the characterisation of this type of breast cancer as slow-proliferating [105, 106].